{"product_id":"arthrex-five-forces-analysis","title":"Arthrex Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eArthrex operates in a high-tech orthopedics niche where supplier specialization and regulatory barriers limit new entrants, while strong dealer relationships and product differentiation temper buyer and substitute threats; competitive rivalry remains intense among innovators. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Arthrex’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Grade Material Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of orthopedic implants uses high-grade materials—medical titanium, cobalt‑chrome, and PEEK polymers—that meet strict FDA and MDR standards, which in 2024 left fewer than 120 globally certified suppliers, giving suppliers moderate bargaining power. Because certified suppliers carry premium pricing—titanium rod prices rose ~18% in 2023—Arthrex must keep stable, long-term contracts to avoid supply shocks. Maintaining these vendor relationships is critical for Arthrex’s global manufacturing footprint and inventory turns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological Complexity of Imaging Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArthrex depends on advanced sensors and optical modules for its Synergy imaging and arthroscopic cameras, sourced from a handful of specialized electronics makers holding key IP; suppliers like Sony and OmniVision control ~60–70% of global high-end CMOS sensor capacity as of 2024, making supplier power high.\u003c\/p\u003e\n\u003cp\u003eA single-site disruption or IP restriction could delay integrated surgical suite deliveries, potentially cutting quarterly equipment revenue by an estimated 10–15% based on Arthrex’s 2023 equipment mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers must meet ISO 13485 and FDA QSR 21 CFR Part 820, creating a high barrier to entry; in 2024 about 60% of medtech suppliers reported certification costs above $150k, narrowing the supplier pool. \u003c\/p\u003e\n\u003cp\u003eArthrex faces slow partner switches because recertification and validation typically take 6–12 months and cost millions for surgical device lines, raising switching costs. \u003c\/p\u003e\n\u003cp\u003eAs a result, incumbent suppliers gain leverage—price, lead-time, and quality negotiation power—impacting Arthrex’s margins and supply agility. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologic Source Material Availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Arthrex expands its orthobiologics lineup, dependence on high-quality donor tissue and niche processing agents rises, and suppliers gain leverage; in 2024 the US tissue bank sector saw a 12% supply shortfall versus demand for musculoskeletal grafts, pushing prices up about 8–10% year-over-year.\u003c\/p\u003e\n\u003cp\u003eEthical sourcing rules and ~200 FDA-registered human tissue processors nationwide constrain volume, so specialized biologics providers can dictate pricing tiers and allocation priorities, impacting Arthrex’s margin planning and launch cadence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 US graft shortfall ~12%\u003c\/li\u003e\n\u003cli\u003ePrice pressure +8–10% YoY (2024)\u003c\/li\u003e\n\u003cli\u003e~200 FDA-registered tissue processors (2024)\u003c\/li\u003e\n\u003cli\u003eHigh supplier leverage on volume and lead times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForward Integration Threats\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpwhile most raw-material suppliers lack expertise to make finished orthopedic devices large chemical and metal conglomerates arcelormittal basf expanding into component manufacturing raising forward-integration risk in global medical device contract grew highlighting scale economies.\u003e\u003cparthrex reduces this threat via deep proprietary design ip and specialized finishing processes private-tooling surface treatments cut rejection rates by in peer studies value capture upstream.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScale: contract manufacturing $93.5B (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: conglomerates expanding component lines\u003c\/li\u003e\n\u003cli\u003eDefense: proprietary IP, specialized finishing\u003c\/li\u003e\n\u003cli\u003eImpact: lower rejection ~30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/parthrex\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: limited certified vendors, CMOS dominance, rising tissue costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-high power: certified implant-material and sensor vendors are few (≈120 certified suppliers; Sony\/OmniVision ≈60–70% CMOS capacity, 2024), recertification takes 6–12 months, and tissue shortages (US graft shortfall ≈12%, ~200 FDA processors) raised prices 8–10% YoY, pressuring Arthrex margins and lead times.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified suppliers\u003c\/td\u003e\n\u003ctd\u003e≈120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOS share (high-end)\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS graft shortfall\u003c\/td\u003e\n\u003ctd\u003e≈12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTissue processors (US)\u003c\/td\u003e\n\u003ctd\u003e≈200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice pressure YoY\u003c\/td\u003e\n\u003ctd\u003e+8–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Mfg market\u003c\/td\u003e\n\u003ctd\u003e$93.5B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Arthrex, this Porter's Five Forces analysis uncovers competitive intensity, supplier and buyer power, entry barriers, substitutes, and disruptive threats shaping its surgical device market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces for Arthrex—quickly spot competitive pressures and opportunities to guide product strategy and M\u0026amp;A decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Systems and GPOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US hospital sector saw 63% of hospitals tied to systems by 2023, and the top 10 GPOs covered ~90% of purchasing spend, giving buyers huge leverage to demand volume discounts that squeeze device margins.\u003c\/p\u003e\n\u003cp\u003eArthrex must prove superior clinical outcomes and 15–25% total-cost-of-care savings in trials or risk delisting from large-system formularies and losing negotiated share to lower-cost rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon Preference and Brand Loyalty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual orthopedic surgeons often favor the tools and implants they trained on, reducing hospital purchasing leverage; surgeon-driven choice accounts for roughly 40%–60% of implant selection in US hospitals per 2023 procurement studies. Arthrex invests about $100 million annually in global education, cadaver labs, and 70+ training centers to cement brand loyalty and procedural familiarity. When surgeons insist on Arthrex for perceived reliability and ease of use, hospitals face higher switching costs and lower bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care and Procurement Metrics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs hospitals shift to value-based care, buyers judge Arthrex by total cost of care—procedure time, recovery speed, and revision rates—rather than unit price; CMS estimates value-based programs covered 40% of Medicare payments by 2022 and rising.\u003c\/p\u003e\n\u003cp\u003eArthrex can justify premiums by showing clinical data: arthroscopy devices that cut OR time by 15–25% and reduce revisions by 10–30% lower per-case costs by thousands of dollars, per hospital studies and 2024 registries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Transparency and Digital Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rise of digital procurement platforms increased price transparency in orthopedics; a 2024 Vizient report showed 18% more hospitals using e-procurement, letting buyers compare device costs faster and pressuring Arthrex on price.\u003c\/p\u003e\n\u003cp\u003eArthrex ties pricing to tech advantages and sells bundled solutions—procedure kits, training, and service—so buyers pay for outcomes not just unit price; bundles drove ~22% of Arthrex revenue in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% more hospitals use e-procurement (Vizient, 2024)\u003c\/li\u003e\n\u003cli\u003eTransparency intensifies price pressure vs tech premium\u003c\/li\u003e\n\u003cli\u003eBundles (kits+training+service) = ~22% revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs and Specialized Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOnce a surgical team is trained on the Arthrex Synergy system or specific arthroscopic instruments, switching to a competitor incurs high time costs and potential clinical risk, creating technical lock-in that reduces churn.\u003c\/p\u003e\n\u003cp\u003eHospitals reporting integrated OR investments often cite $250k–$1.2M per suite; combined with staff training (20–80 hours per surgeon), these sunk costs make exit costly and favor Arthrex pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTraining: 20–80 hours per surgeon\u003c\/li\u003e\n\u003cli\u003eIntegrated OR cost: $250k–$1.2M per suite\u003c\/li\u003e\n\u003cli\u003eTechnical lock-in lowers price sensitivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ leverage vs. Arthrex lock‑in: GPOs, e‑procurement and surgeon preference collide\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers wield strong leverage: 90% of hospital spend flows through top 10 GPOs and 63% hospitals are system-affiliated (2023), forcing price pressure; e-procurement rose 18% (Vizient, 2024), increasing transparency. Surgeon preference (40–60% implant choice) and Arthrex’s $100M\/year training, 70+ centers, and bundles (~22% revenue, 2024) create technical lock-in that preserves premiums tied to demonstrated 15–25% OR time cuts and 10–30% lower revisions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals system-affiliated (2023)\u003c\/td\u003e\n\u003ctd\u003e63%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 10 GPO spend coverage\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE-procurement uptake (2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining spend (Arthrex)\u003c\/td\u003e\n\u003ctd\u003e$100M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBundles revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon-driven choice\u003c\/td\u003e\n\u003ctd\u003e40–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eArthrex Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Arthrex Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders or samples. It’s the professionally formatted, complete document ready for download and use the moment you buy. The content covers supplier power, buyer power, competitive rivalry, threat of substitution, and entry barriers with actionable insights. No surprises—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747595563385,"sku":"arthrex-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/arthrex-five-forces-analysis.png?v=1772200177","url":"https:\/\/matrixbcg.com\/products\/arthrex-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}